Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01152788 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
A Phase 2 study, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT01152788 is a Phase 2 study that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 64 participants.
The verdict
NCT01152788, a Phase 2 study, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects an experimental drug, called interleukin 21 or rIL-21, will have on malignant melanoma and whether these effects look promising compared to dacarbazine. In addition, this study will look at the side effects of rIL-21, and some special blood tests will be done to check the level of rIL-21 in the blood. This study will also look at previously removed melanoma tissue to determine which patients might benefit most from this treatment. This research is being done because currently there is no effective treatment for this type of cancer.
Interventions
- DRUG Dacarbazine
- DRUG rIL-21
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2010-08-05 |
| Est. Completion | 2015-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01152788
The ClinicalTrials.gov registry entry for NCT01152788 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dacarbazine is the first listed.
NCT01152788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01152788 about?
NCT01152788 is a clinical study titled "Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma". The purpose of this study is to find out what effects an experimental drug, called interleukin 21 or rIL-21, will have on malignant melanoma and whether these effects look promising compared to dacarbazine. In addition, this study will look at the side effects of rIL-21, and some special blood tests...
What is the current status of trial NCT01152788?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2010-08-05. Estimated completion is 2015-02-13.
What interventions are being tested in trial NCT01152788?
The interventions under investigation include: Dacarbazine (DRUG), rIL-21 (DRUG).
Who is sponsoring clinical trial NCT01152788?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.